MedTrace Logo

The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.

NCT06753071 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-03-26

No results posted yet for this study

Summary

The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder

Conditions

  • Underactive Bladder
  • TURP(transurethral Resection of Prostate)
  • BPH (Benign Prostatic Hyperplasia)

Interventions

DRUG

Pyridostigmine oral tablet

Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months

DRUG

Placebo

Placebo oral tablet, twice daily, for 3 months

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-07-01
Completion
2025-01-01
FDA Drug
Yes

Countries

  • Egypt

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06753071 on ClinicalTrials.gov